Literature DB >> 17823118

Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility.

Tracy L Criswell1, Carlos L Arteaga.   

Abstract

Transforming growth factor beta is growth-inhibitory in non-transformed epithelial cells but becomes growth-promoting during tumorigenesis. The role of the type I and II receptors in tumorigenesis has been extensively studied, but the role of the ubiquitously expressed type III receptor (TbetaRIII) remains elusive. We developed short hairpin RNAs directed against TbetaRIII to investigate the role of this receptor in breast cancer tumorigenesis. Nontumorigenic NMuMG mouse cells stably expressing short hairpin RNA specific to mouse TbetaRIII (NM-kd) demonstrated increased cell growth, motility, and invasion as compared with control cells expressing shRNA to human TbetaRIII (NM-con). Reconstitution of TbetaRIII expression with rat TbetaRIII abrogated the increased growth and motility seen in the NM-kd cells. In addition, the NM-kd cells exhibited marked reduction in the expression of the adherens junction protein, E-cadherin. This loss of E-cadherin was due to increased NFkappaB activity that, in turn, resulted in increased expression of the transcriptional repressors of E-cadherin such as Snail, Slug, Twist, and Sip1. Finally, NMuMG cells in which TbetaRIII had been knocked down formed invasive tumors in athymic nude mice, whereas the control cells did not. These data indicate that TbetaRIII acts as a tumor suppressor in nontumorigenic mammary epithelial cells at least in part by inhibiting NFkappaB-mediated repression of E-cadherin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17823118     DOI: 10.1074/jbc.M704434200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Myosin II isoform switching mediates invasiveness after TGF-β-induced epithelial-mesenchymal transition.

Authors:  Jordan R Beach; George S Hussey; Tyler E Miller; Arindam Chaudhury; Purvi Patel; James Monslow; Qiao Zheng; Ruth A Keri; Ofer Reizes; Anne R Bresnick; Philip H Howe; Thomas T Egelhoff
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-24       Impact factor: 11.205

Review 2.  Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.

Authors:  James A McCubrey; Stephen L Abrams; Kristin Stadelman; William H Chappell; Michelle Lahair; Richard A Ferland; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2009-11-04

Review 3.  Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Authors:  Mark A Feitelson; Alla Arzumanyan; Rob J Kulathinal; Stacy W Blain; Randall F Holcombe; Jamal Mahajna; Maria Marino; Maria L Martinez-Chantar; Roman Nawroth; Isidro Sanchez-Garcia; Dipali Sharma; Neeraj K Saxena; Neetu Singh; Panagiotis J Vlachostergios; Shanchun Guo; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Alan Bilsland; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; W Nicol Keith; Somaira Nowsheen
Journal:  Semin Cancer Biol       Date:  2015-04-17       Impact factor: 15.707

4.  Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells.

Authors:  Maree Bilandzic; Simon Chu; Yao Wang; Han L Tan; Peter J Fuller; Jock K Findlay; Kaye L Stenvers
Journal:  Mol Endocrinol       Date:  2013-01-15

5.  The type III TGF-beta receptor suppresses breast cancer progression through GIPC-mediated inhibition of TGF-beta signaling.

Authors:  Jason D Lee; Nadine Hempel; Nam Y Lee; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2009-12-02       Impact factor: 4.944

6.  TNF-α signals through PKCζ/NF-κB to alter the tight junction complex and increase retinal endothelial cell permeability.

Authors:  Célia A Aveleira; Cheng-Mao Lin; Steven F Abcouwer; António F Ambrósio; David A Antonetti
Journal:  Diabetes       Date:  2010-08-06       Impact factor: 9.461

7.  Requirement of the Akt/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug.

Authors:  Makoto Saegusa; Miki Hashimura; Takeshi Kuwata; Isao Okayasu
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

8.  Size-dependent regulation of Snail2 by hyaluronan: its role in cellular invasion.

Authors:  Evisabel A Craig; Patti Parker; Todd D Camenisch
Journal:  Glycobiology       Date:  2009-05-18       Impact factor: 4.313

Review 9.  Twist: a molecular target in cancer therapeutics.

Authors:  Md Asaduzzaman Khan; Han-chun Chen; Dianzheng Zhang; Junjiang Fu
Journal:  Tumour Biol       Date:  2013-07-20

10.  Type III transforming growth factor-beta (TGF-beta) receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-beta signaling pathway.

Authors:  Vitaly Margulis; Tapati Maity; Xiu-Ying Zhang; Simon J Cooper; John A Copland; Christopher G Wood
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.